Caliway Submits IND for Phase 2 Study of CBL-514 Combined with Zepbound for Weight Management
Key Insights
Caliway Biopharmaceuticals (search) has completed submission of an IND application to the U.S. FDA for a Phase 2 clinical study evaluating CBL-514 in combination with Eli Lilly's Zepbound (tirzepatide) for weight management.
The randomized, placebo-controlled study will enroll approximately 120 subjects with obesity (search) or overweight (search) and assess changes in abdominal subcutaneous fat volume and body weight as primary endpoints.
CBL-514 represents the world's first large-area localized fat reduction drug that induces adipocyte apoptosis, offering a novel mechanism distinct from GLP-1RA therapies that primarily work through appetite suppression.
Caliway Biopharmaceuticals (search) has completed submission of an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (search) for a Phase 2 clinical study of CBL-514, positioning the company to advance its novel fat reduction therapy in combination with established GLP-1 receptor (search) agonist treatments. The submission marks a significant milestone for what the company describes as the world's first large-area localized fat reduction drug candidate.
Study Design and Objectives
The CBL-0201WR Phase 2 study is designed as a randomized, placebo-controlled trial to be conducted at multiple centers in the United States. The study is expected to enroll approximately 120 subjects with obesity (search) (BMI > 30) or overweight (search) (BMI > 27) with comorbidities.
The trial will evaluate the efficacy, safety, and tolerability of CBL-514 in combination with Zepbound (tirzepatide), Eli Lilly's dual GLP-1/GIP receptor (search) agonist. Primary efficacy endpoints include changes in abdominal subcutaneous fat volume measured by MRI and changes in body weight. The study will also collect comprehensive body composition data using DEXA (dual-energy X-ray absorptiometry), including body fat percentage, visceral fat, and muscle mass.
To ensure data integrity, MRI and DEXA data will be read and analyzed in a blinded and independent manner by a third-party contract research organization before statistical analyses are performed.
Addressing Treatment Limitations
The study design specifically addresses a critical limitation of current GLP-1RA therapies. While these treatments can substantially reduce body weight through appetite suppression, clinical evidence indicates they mainly shrink adipocyte size without reducing adipocyte number, with limited effects on abdominal subcutaneous fat reduction.
According to the company, during GLP-1RA treatment, profound appetite suppression induces a prolonged negative energy balance, triggering compensatory mechanisms and the intrinsic "memory" of adipocytes (search) to restore their size. Once appetite returns after treatment discontinuation, these shrunken adipocytes may preferentially re-accumulate energy, undergo rapid enlargement and expansion, and be accompanied by increased visceral fat accumulation and deterioration of metabolic indicators, including insulin resistance (search).
Novel Mechanism of Action
CBL-514 offers a distinct mechanism of action compared to GLP-1RA therapies. For weight management applications, CBL-514 acts through selective induction of adipocyte apoptosis, directly targeting adipocytes (search). Based on completed studies, the drug has also been shown to inhibit adipogenesis and promote fat metabolism, potentially offering complementarity when combined with GLP-1RA treatments that primarily regulate appetite and energy intake.
In the CBL-0201WR study, CBL-514 will be added after 8 weeks of tirzepatide monotherapy, with six combination administrations. Following the treatment period, subjects will undergo longitudinal follow-up to assess abdominal subcutaneous fat changes, body weight changes, fat mass, and body composition-related parameters.
Preclinical Evidence and Market Context
Data from multiple animal studies have demonstrated that CBL-514, whether used alone or in combination with GLP-1RA therapies, has the potential to improve fat composition and support weight maintenance. The latest animal study results were presented on December 14 at the 25th Annual Congress of the Taiwan Medical Association for the Study of Obesity (search) (TMASO 2025). The study, titled "Combination CBL-514 and Tirzepatide Synergistically Enhances Adiposity Reduction and Maintains Weight Loss After Tirzepatide Withdrawal," was delivered as an oral presentation by Dr. Tzu-Jung Chou of National Taiwan University Hospital Hsinchu Branch (search).
The market opportunity for innovative weight management therapies continues to expand rapidly. According to market data cited by the company, cumulative sales of tirzepatide reached approximately $24.8 billion in the first three quarters of 2025. Morgan Stanley Research (search) projects that the global weight-loss drug market could reach approximately $150 billion by 2035, representing a compound annual growth rate of around 25 percent.
Drug Development Profile
CBL-514 is described as a 505(b)(1) and first-in-class small-molecule drug that represents the world's first injectable lipolysis drug inducing adipocyte apoptosis to reduce subcutaneous fat in targeted areas. To date, 10 clinical trials with a total of 544 subjects have been completed with all efficacy and safety endpoints met, with no systematic safety risks identified.
The drug is being developed across multiple indications, including reduction of subcutaneous fat (non-surgical localized fat reduction), moderate-to-severe cellulite (search), and weight management. A related formulation, CBL-514D (search), containing the same active pharmaceutical ingredients but under different formulation, is being studied for additional indications such as Dercum's disease (search).